Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Fineline Cube Jun 16, 2026
Company Deals

Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets

Fineline Cube Jun 16, 2026
Company Deals

AstraZeneca Joins ZERO Prostate Cancer’s Blitz the Barriers Initiative – Ambitious Program Aims to Save 100,000 Lives by 2035

Fineline Cube Jun 16, 2026
Company Deals

Johnson & Johnson Invests $1 Billion in Jacksonville Vision Facility – Expands ACUVUE Manufacturing and Distribution

Fineline Cube Jun 16, 2026
Company Deals

Lynk Pharmaceuticals Files for Hong Kong IPO – Autoimmune Pipeline Led by JAK Inhibitors and Novel Protein Degraders

Fineline Cube Jun 16, 2026
Policy / Regulatory

China’s NHSA Receives Record 818 Drug Applications for 2026 National Reimbursement Drug List Adjustment

Fineline Cube Jun 15, 2026
Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Fineline Cube Jun 16, 2026
Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Fineline Cube Jun 16, 2026
Company Deals

Medlander Medical Technology’s IPO Raises RMB 1 billion on Shanghai’s STAR Board

Fineline Cube Aug 12, 2022

Medlander Medical Technology Inc., a leading Chinese manufacturer of pelvic floor rehabilitation equipment, has completed...

Company Drug

InnoCare Pharma’s Orelabrutinib sNDA Accepted for Marginal Zone Lymphoma

Fineline Cube Aug 12, 2022

InnoCare Pharma (HKG: 9969) announced that a supplemental New Drug Application (sNDA) for its Bruton’s...

Company Deals

TianShiWei Raises Tens of Millions in Series A for Medical Aesthetics Expansion

Fineline Cube Aug 12, 2022

hina-based Wuhan TianShiWei Biotechnology Co., Ltd has reportedly raised tens of millions of renminbi in...

Company Deals

BeiGene Partners with Jilin Cancer Hospital for Cancer Drug Development

Fineline Cube Aug 12, 2022

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a clinical study partnership...

Policy / Regulatory

China Ramps Up Monitoring of Clinically Shortage Drugs Involving 109 Varieties

Fineline Cube Aug 12, 2022

The Ministry of Industry and Information Technology (MIIT), National Health Commission (NHC), National Healthcare Security...

Company Drug

Arbele’s ARB202 Enters Phase I Trial for Advanced Gastrointestinal Cancer

Fineline Cube Aug 11, 2022

Hong Kong-based biopharma Arbele announced that its CDH17 × CD3 bispecific T-Cell engager antibody, ARB202,...

Deals Hospital

ByteDance Acquires Amcare Healthcare for USD1.5b via Xiaohe Health Unit

Fineline Cube Aug 11, 2022

ByteDance Ltd, the parent company of social media platforms TikTok and Douyin, has acquired Amcare...

Company Deals Legal / IP Policy / Regulatory

Taihu Bay Healthcare Conference Launches Wuxi IP Protection Center

Fineline Cube Aug 11, 2022

The 2022 Taihu Bay Future Healthcare Conference was held in Wuxi City, Jiangsu province, China,...

Company Deals

United Imaging Healthcare’s STAR Listing Raises USD1.85 Billion

Fineline Cube Aug 11, 2022

Shanghai-based United Imaging Healthcare (UIH) has completed an initial public offering (IPO) of 100 million...

Company Medical Device

Boston Scientific’s Rezūm System Installed in China’s Urinary Innovation Center

Fineline Cube Aug 11, 2022

US major Boston Scientific Corporation (NYSE: BSX) has jointly established the “Urinary Joint Innovation Center”...

Company Deals

Trautec Medical Raises RMB200m in Series A Financing for Recombinant Collagen R&D

Fineline Cube Aug 11, 2022

China-based Jiangsu Trautec Medical Technology Co., Ltd. has reportedly raised nearly RMB200 million (USD205.3 million)...

Drug

Zhaoke Ophthalmology Enrolls First Patient in ZKY001 Phase II TPRK Study

Fineline Cube Aug 11, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) announced the...

Company Deals

Insilico Medicine Closes USD95m Series D Financing to Advance AI Drug Discovery

Fineline Cube Aug 11, 2022

Insilico Medicine, a Hong Kong-based artificial intelligence (AI)-driven drug discovery company, announced the closure of...

Company Drug

LianBio Completes Enrollment for Mavacamten Phase III Trial in oHCM

Fineline Cube Aug 11, 2022

China-based biotech LianBio (OTCMKTS: LIANY) announced that enrollment has been completed in the Phase III...

Company Deals

Huadong Medicine to Acquire 60% Stake in Wuhu Huaren for RMB 396 Million

Fineline Cube Aug 11, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical...

Company Drug

Recbio Completes Enrollment for HPV Vaccine REC603 Immuno-Bridging Study

Fineline Cube Aug 11, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of subject...

Company Deals Drug

Everest Medicines’ Xerava NDA Accepted by Taiwan’s TFDA

Fineline Cube Aug 11, 2022

Everest Medicines (HKG: 1952) announced that its New Drug Application (NDA) for Xerava (eravacycline) for...

Company

China Grand Pharma’s H1 2022 Revenues Up 14.1% to USD664m, R&D Spending Rises

Fineline Cube Aug 11, 2022

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512) published its financial results for the...

Company Drug

HutchMed and AstraZeneca’s Tagrisso-Orpathys Combo Shows Promise in NSCLC Study

Fineline Cube Aug 10, 2022

Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) and AstraZeneca (AZ, NASDAQ: AZN) announced the...

Company Drug

NMPA Accepts Roche’s Crovalimab Filing for PNH Treatment with Priority Review

Fineline Cube Aug 10, 2022

The National Medical Products Administration (NMPA) has officially accepted for review the market filing submitted...

Posts pagination

1 … 656 657 658 … 684

Recent updates

  • Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets
  • Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor
  • Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction
  • Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways
  • Harbour BioMed and BioMap Launch MegaStream TechBio – Next-Generation AI Drug Discovery Company Targeting Global Markets
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Everest Medicines Licenses DMX-200 from Dimerix – CCR2 Inhibitor for FSGS Targets Asia-Pacific Markets

Company Drug

Zelgen Biopharmaceuticals Secures NMPA Approval for Zepuping in Severe Alopecia Areata – First Immuno-Inflammatory Indication for Pan-JAK Inhibitor

Company Drug

Hinova Pharmaceuticals Reports Positive Phase IIa Data for HP515 in MASH – THR-β Agonist Achieves >50% Liver Fat Reduction

Company Drug

Chia Tai Tianqing Presents Positive Phase II Data for TQC2938 in Allergic Rhinitis – Novel ST2-Targeting mAb Shows Efficacy Across Inflammatory Pathways

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.